US Patent 10,463,736: Meloxicam-Bicarbonate Oral Dosage Form Patent Scope, Expiration, and Competitive Landscape

US Patent 10,463,736 protects a specific oral meloxicam delivery profile rather than meloxicam generally. Independent claim 1 requires four core elements: meloxicam, 400 mg to 800 mg of bicarbonate, a solid dosage form for direct oral administration, and a median meloxicam Tmax below one hour in humans. The patent is therefore most relevant to fast-acting meloxicam tablets or capsules, including products containing sodium bicarbonate and, in narrower claims, esomeprazole.

The strongest infringement risk is for a solid, immediate-release meloxicam product containing approximately 15 mg of meloxicam and 400 mg to 800 mg of sodium bicarbonate that demonstrates a median Tmax below one hour under the claimed administration conditions. A conventional meloxicam tablet without bicarbonate does not satisfy the express bicarbonate limitation.

What does US Patent 10,463,736 claim?

Claim 1 is an open-ended composition claim. The word “comprising” permits additional ingredients, including excipients, acid inhibitors, coatings, binders, disintegrants, and other pharmaceutical components, provided the claimed elements are present.

Claim element	Required for claim 1?	Scope
Meloxicam	Yes	Amount is not specified in claim 1
Bicarbonate	Yes	400 mg to 800 mg
Solid dosage form	Yes	Tablet, capsule, or another solid form
Direct oral administration	Yes	Excludes a dosage form requiring prior dissolution or indirect administration
Median meloxicam Tmax below one hour	Yes	Human pharmacokinetic limitation
Sodium bicarbonate	No, unless claim 2 is asserted	Specifically required by claim 2
Potassium bicarbonate	No, unless claim 3 is asserted	Specifically required by claim 3
Esomeprazole or another proton pump inhibitor	No, unless claims 5-10 are asserted	Narrows the composition
15 mg meloxicam	No, unless claim 12 is asserted	Narrow dosage limitation
Tablet or capsule	No, unless claim 14 is asserted	Narrow dosage-form limitation

The independent claim does not require esomeprazole, a particular meloxicam dose, a specific disease, once-daily administration, fasting administration, or a particular excipient. Those limitations appear in dependent claims 5 through 21.

How broad is the independent claim?

Claim 1 covers more than the commercial-style formulation suggested by the dependent claims. It can read on a solid oral dosage form containing:

10 mg, 15 mg, 20 mg, or another amount of meloxicam;
400 mg, 500 mg, 600 mg, 700 mg, or 800 mg of bicarbonate;
sodium bicarbonate, potassium bicarbonate, or another bicarbonate;
no proton pump inhibitor;
one or more additional active ingredients;
a tablet, capsule, or another solid form;
a fasting or fed administration regimen.

The critical limitation is not simply the presence of bicarbonate. The product must also produce a median meloxicam Tmax of less than one hour in human beings when administered directly as the claimed solid dosage form.

That pharmacokinetic limitation materially narrows the claim. A competing product containing meloxicam and bicarbonate may avoid literal infringement if its clinical data show a median Tmax of one hour or longer. Conversely, a product may create infringement exposure even if its label does not promote rapid absorption, if the formulation inherently produces the claimed pharmacokinetic result.

What do claims 2 through 4 protect?

Claims 2 through 4 create a preferred sodium-bicarbonate formulation:

Claim	Limitation
Claim 2	Bicarbonate is sodium bicarbonate
Claim 3	Bicarbonate is potassium bicarbonate
Claim 4	The product of claim 2 contains 500 mg of sodium bicarbonate

Claim 4 is narrower than claim 2 and requires both sodium bicarbonate and 500 mg of that ingredient. A product containing 500 mg of potassium bicarbonate would not satisfy claim 4, although it could remain relevant to claim 3 or claim 1.

The 400 mg to 800 mg range in claim 1 raises ordinary claim-construction issues concerning measurement, salt purity, hydrates, manufacturing tolerances, and whether the claimed amount refers to the bicarbonate ingredient as supplied or the bicarbonate ion equivalent. The patent specification and prosecution history would control those issues.

What formulations are protected by the esomeprazole claims?

Claims 5 through 10 cover combinations of meloxicam, bicarbonate, and an acid inhibitor. Claim 6 narrows the acid inhibitor to a proton pump inhibitor. Claim 7 identifies five alternatives:

esomeprazole;
omeprazole;
lansoprazole;
pantoprazole; and
rabeprazole.

Claims 8 through 10 focus on esomeprazole, with claim 10 requiring approximately 40 mg. Claim 9 covers approximately 30 mg to approximately 50 mg of esomeprazole.

A product containing 15 mg of meloxicam, 500 mg of sodium bicarbonate, and 40 mg of esomeprazole could potentially fall within claims 1, 2, 4, 5, 6, 7, 8, 9, 10, 12, and, if applicable, claims 13 through 21. Multiple claim hits do not create multiple independent infringement causes for the same product, but they increase the number of limitations that may need to be addressed in validity or noninfringement proceedings.

The claims do not require a particular physical separation of meloxicam, bicarbonate, and esomeprazole. A single-layer tablet, multilayer tablet, capsule containing separate particles, or another solid architecture could potentially satisfy the language, subject to the specification and prosecution history.

How do the dosage and administration claims affect scope?

Claims 11 and 12 narrow meloxicam content to approximately 10 mg to approximately 20 mg and approximately 15 mg, respectively. The use of “about” creates a tolerance question. Courts generally interpret “about” in the context of the intrinsic record, including examples, analytical precision, formulation practice, and prosecution statements.

Claims 15 through 17 address administration:

claim 15: fasting conditions;
claim 16: once-daily administration;
claim 17: once-daily administration for at least six days.

These claims are method-linked limitations embedded in an oral dosage-form claim. Their practical value depends on how the claims are construed and whether the accused product is reasonably tied to the specified administration conditions.

Claims 19 through 21 cover use to treat:

pain;
arthritis; and
migraine.

These disease limitations may be difficult to enforce against a product with a broad label unless the label, prescribing information, marketing, or actual use supports the claimed indication. Claim 21 may be commercially significant because migraine treatment depends heavily on rapid onset, but the product must still satisfy the formulation and pharmacokinetic limitations inherited from claim 1.

What is the likely patent expiration date?

US Patent 10,463,736 issued on November 5, 2019. The enforceable term is generally calculated as 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any applicable priority-chain effects under 35 U.S.C. § 154.

The grant date alone does not establish the expiration date. The patent’s exact term requires review of the front-page priority data, continuity statements, terminal disclaimer records, and USPTO Patent Center term information. A 2019 issue date does not mean that exclusivity runs to 2039.

For diligence purposes, the relevant term fields are:

Term issue	Business effect
Earliest nonprovisional filing date	Establishes the baseline 20-year term
Patent-term adjustment	Can extend the baseline term
Terminal disclaimer	Can shorten the term to match another patent
Patent-term extension under 35 U.S.C. § 156	May apply only if statutory requirements are met
Continuation or divisional status	Does not automatically reset the 20-year term
PTA certificate and USPTO calculation	Controls the operative expiration date

The patent should not be assigned a precise expiration date without the USPTO term record. The statutory framework is set out in 35 U.S.C. § 154, and the patent’s official record is maintained by the USPTO. [1, 2]

What is the Orange Book status of US Patent 10,463,736?

A patent number is not automatically an Orange Book patent. FDA listing depends on whether an NDA holder submitted the patent for an approved drug and whether the patent covers the drug substance, drug product, or an approved method of use under FDA’s listing rules. [3]

The claims supplied here are formulation and pharmacokinetic claims directed to a meloxicam-bicarbonate oral dosage form. They do not establish that the patent is listed in the Orange Book for any approved NDA. The patent’s Orange Book impact therefore depends on three separate facts:

whether an approved product practices the claimed formulation;
whether the NDA holder submitted the patent to FDA;
whether FDA accepted the patent for listing.

An unlisted patent may remain enforceable under ordinary patent law, but it generally does not trigger the same statutory Paragraph IV certification process as an Orange Book-listed patent.

When does a generic applicant face Paragraph IV risk?

A generic applicant faces Paragraph IV risk if it files an ANDA referencing an NDA product and certifies that a listed patent is invalid, unenforceable, or will not be infringed. The applicant must identify the patent and provide the required notice to the patent owner and NDA holder. [4]

For this patent, the principal Paragraph IV theories would likely involve:

noninfringement because the product contains no bicarbonate;
noninfringement because bicarbonate is below 400 mg or above 800 mg;
noninfringement because the formulation is not a solid dosage form for direct administration;
noninfringement because median Tmax is not below one hour;
invalidity for anticipation;
invalidity for obviousness based on meloxicam, bicarbonate, rapid-release formulations, and known pharmacokinetic objectives;
indefiniteness involving “about,” “well tolerated,” or the Tmax limitation;
enablement or written-description challenges to the breadth of the claimed formulation and performance range.

The Tmax limitation may create a substantial technical dispute. A challenger would likely demand the patent holder’s clinical and statistical methodology, including subject population, fasting status, sampling intervals, assay method, treatment sequence, and handling of censored or tied observations.

How strong is the patent estate?

The patent appears to have meaningful claim differentiation but a narrower commercial perimeter than a basic meloxicam patent.

Strength factor	Assessment
Core composition	Stronger because it requires a defined bicarbonate range and pharmacokinetic outcome
Generic meloxicam products	Limited direct exposure if they lack bicarbonate
Sodium-bicarbonate products	Higher exposure, especially at 500 mg
Esomeprazole combinations	Higher exposure under claims 5-10
15 mg products	Higher exposure under claim 12
Fast-onset products	Higher exposure if clinical data establish median Tmax below one hour
Conventional tablets	Lower exposure if they lack the bicarbonate and Tmax profile
Method-of-use claims	Dependent on label content and actual use
Validity	Depends on prior art and enablement of the sub-one-hour performance

The patent’s principal value lies in the combination of composition and pharmacokinetics. That structure can make design-around easier than for a broad composition patent, but it also gives the patent holder a potentially strong position against a product intentionally engineered for rapid onset using the same bicarbonate approach.

What generic launch scenarios exist?

Scenario 1: Conventional meloxicam generic

A standard meloxicam tablet without bicarbonate is unlikely to meet claim 1 literally. Its principal risk would arise only if the formulation contains an undisclosed bicarbonate component or if an asserted claim is interpreted unusually broadly.

Scenario 2: Rapid-release meloxicam with less than 400 mg bicarbonate

This product may avoid claim 1’s express range. It could still face arguments under other patent claims in the family, if any, or under the doctrine of equivalents. The numerical range would be central to the dispute.

Scenario 3: Rapid-release meloxicam with 500 mg sodium bicarbonate

This is the highest-risk design under the supplied claims. If the product is a direct-use tablet or capsule and its median Tmax is below one hour, it could implicate claims 1, 2, and 4, as well as dose-specific claims if it contains approximately 15 mg meloxicam.

Scenario 4: Meloxicam plus esomeprazole

A product containing 30 mg to 50 mg of esomeprazole, particularly approximately 40 mg, creates additional exposure under claims 5 through 10. The product may also encounter separate intellectual-property issues relating to esomeprazole formulation, stereochemistry, delayed release, and PPI stability.

Scenario 5: Alternative bicarbonate or alkalizing agent

Potassium bicarbonate is expressly captured by claim 3. A non-bicarbonate alkalizing agent may avoid the literal bicarbonate limitation, although the formulation could face separate patents or an equivalents argument depending on the evidence.

What litigation and licensing issues matter?

The supplied claim set does not establish a litigation docket, settlement agreement, license, Orange Book listing, or authorized generic arrangement. Those issues require review of PACER, USPTO assignment records, FDA Orange Book data, and SEC filings for the relevant patent owner, NDA holder, and commercial partners.

For transaction diligence, the material questions are:

whether the patent has been challenged under Paragraph IV;
whether any terminal disclaimer limits its term;
whether the patent is part of a continuation family;
whether related patents claim manufacturing, particle size, coating, or dissolution;
whether the commercial product is licensed from the patent owner;
whether a settlement permits an early generic launch;
whether the patent owner has granted field-of-use or geographic rights.

A license covering the patent would not necessarily cover related continuation patents, foreign counterparts, know-how, or manufacturing rights.

How does this patent compare with ordinary meloxicam patent protection?

US Patent 10,463,736 is formulation-specific. It does not claim:

meloxicam as a chemical entity;
every meloxicam tablet;
every meloxicam use;
every rapid-release meloxicam product;
every meloxicam product containing an acid inhibitor.

Its protection depends on the combination of bicarbonate quantity, solid dosage form, direct administration, and measured human Tmax. That makes it narrower than an active-ingredient patent but potentially more relevant to a fast-onset product designed around the claimed formulation concept.

Key Takeaways

Claim 1 requires meloxicam, 400 mg to 800 mg of bicarbonate, a solid direct-oral dosage form, and a median Tmax below one hour.
Claims 2 and 4 create focused protection for sodium bicarbonate, including 500 mg.
Claim 3 separately covers potassium bicarbonate.
Claims 5 through 10 extend the formulation to proton pump inhibitors, with particular emphasis on 30 mg to 50 mg of esomeprazole and approximately 40 mg.
Claims 11 and 12 target approximately 10 mg to 20 mg and approximately 15 mg of meloxicam.
Claims 15 through 21 add fasting, once-daily, tolerability, pain, arthritis, and migraine limitations.
Conventional meloxicam generics without bicarbonate have a lower direct infringement profile.
A 15 mg meloxicam, 500 mg sodium bicarbonate, rapid-onset tablet is the clearest high-risk design.
The patent’s exact expiration date cannot be determined from the grant number or claim text alone because USPTO term adjustment, terminal disclaimer, and priority data control.
Orange Book listing and Paragraph IV consequences are not established by the patent claims themselves.

Frequently Asked Questions

Does US Patent 10,463,736 cover Mobic or all meloxicam products?

No. The claims require bicarbonate and a median meloxicam Tmax below one hour. A conventional meloxicam product without those characteristics is outside the literal scope of claim 1.

Can a product avoid the patent by using 300 mg of sodium bicarbonate?

Potentially, with respect to claim 1, because that claim requires 400 mg to 800 mg. The complete patent family and doctrine-of-equivalents risk would still require separate analysis.

Does claim 1 require esomeprazole?

No. Esomeprazole appears only in dependent claims 8 through 10. Claim 1 can cover a meloxicam-bicarbonate product without a proton pump inhibitor.

Is a meloxicam capsule automatically covered?

No. Capsule form is expressly identified in claim 14, but the product must also satisfy the limitations inherited from claim 1, including the bicarbonate range and sub-one-hour median Tmax.

Does a sub-one-hour Tmax prove infringement?

No. It is one required limitation, not the entire test. Infringement also depends on the presence of meloxicam, the required bicarbonate amount, the solid dosage form, direct administration, and any limitations of the particular asserted claim.

References

United States Patent and Trademark Office. (n.d.). Patent term adjustment. https://www.uspto.gov/patents/laws/patent-term-adjustment
United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (n.d.). ANDA submissions: Content, format, and review. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs
United States Congress. (2012). 35 U.S.C. § 154: Contents and term of patent; provisional rights. https://uscode.house.gov/Viewer.xhtml?req=granuleid:USC-prelim-title35-section154&num=0&edition=prelim

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes	10,463,736	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016218992	⤷ Start Trial
Australia	2018205790	⤷ Start Trial
Australia	2018265411	⤷ Start Trial
Australia	2019203328	⤷ Start Trial
Australia	2019297360	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,463,736

Which drugs does patent 10,463,736 protect, and when does it expire?

Summary for Patent: 10,463,736